Siponimod cuts risk of disability progression in multiple sclerosis

Siponimod cuts risk of disability progression in multiple sclerosis

(HealthDay)—For patients with secondary progressive multiple sclerosis, the selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, siponimod, is associated with reduced relative risk of confirmed disability progression, according to a study published online March 22 in The Lancet.

Ludwig Kappos, M.D., from the University of Basel in Switzerland, and colleagues conducted a phase 3 trial at 292 hospital clinics and specialized centers in 31 countries. Patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 were randomized in a 2:1 ratio to once-daily oral siponimod 2 mg or placebo. A total of 1,645 patients were included in the analyses: 1,099 to the siponimod group and 546 to the ; 903 and 424 patients completed the study, respectively.

The researchers found that 26 and 32 percent of patients receiving siponimod and placebo had three-month confirmed disability progression events (hazard ratio, 0.79; relative risk reduction, 21 percent). Adverse events occurred in 89 and 82 percent of taking siponimod and placebo, respectively; serious were reported for 18 and 15 percent, respectively.

"Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures siponimod and funded the study.

Explore further

Cannabidiol efficacious for lennox-gastaut drop seizures

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: The Lancet

Copyright © 2018 HealthDay. All rights reserved.

Citation: Siponimod cuts risk of disability progression in multiple sclerosis (2018, March 23) retrieved 22 June 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments